Prescient Surgical was founded by a team from the Biodesign Fellowship program at Stanford University. The company has assembled a world-class team of operational and medical & scientific leaders committed to reducing the risk of surgical site infection.
Jon has over 10 years of diverse operational experience in the medical device industry. Before co-founding Prescient Surgical as a Stanford Biodesign Innovation Fellow, Jon held a range of roles in engineering, marketing, and leadership in the surgical instrument divisions of Johnson & Johnson and Covidien. Jon is an inventor on over 25 issued patents and successfully launched 4 major products in bariatric, general, and natural orifice surgery and surgical oncology. Jon also started 2 interventional cardiology companies, Metavention and Gradient Therapeutics, and led the IP, technical, and pre-clinical efforts at Metavention through a successful Series B investment. Jon holds SB and MS degrees in Mechanical Engineering from MIT and Georgia Tech, respectively.
Insoo Suh, MD is a board-certified endocrine and general surgeon at the San Francisco VA Medical Center, and serves on the faculty of the University of California, San Francisco (UCSF) Department of Surgery. He co-founded Prescient Surgical and leads the company’s clinical development, providing the clinical insight and design feedback critical to making a superior surgical product. Dr. Suh received a BS in Molecular Biophysics and Biochemistry from Yale University, and completed his medical and surgical training at UCSF. After residency, he pursued the Stanford Biodesign Innovation fellowship out of which Prescient Surgical was founded. Dr. Suh has authored numerous peer-reviewed publications, book chapters, and patent applications, and has been recognized on many occasions for his achievements in academic surgery and innovation.
Mark Lane Welton, the Harry A. Oberhelman Jr, Professor and Chief of Colon and Rectal Surgery is Chief of Staff for Stanford Hospital and Clinics. He served as Vice Chief from 2011 to 2014. Dr. Welton joined the medical staff in September 2001 as a fulltime member in the Stanford University School of Medicine. Over that time he has grown the Colorectal Surgery section from one member to five full time faculty. Dr. Welton has held several leadership roles in the medical center including the inaugural unit-based medical director for the E-3 med/surg nursing unit, co-founder of the Surgical Quality Council, Medical Director for the Clinical Cancer Center (April ’08 – July ’10), and Gastrointestinal Cancer Care Program Physician Lead (April 2010 – present). While Interim Medical Director he won the Blake Wilbur space for the expansion of the Clinical Cancer Center. He developed the vision and created the business proposal for the Women’s Cancer Center to occupy that space. He developed the concept of Cancer Care Programs resulting in the reorganization of patient care delivery in the Clinical Cancer Center.
Dr. Welton received his MD and completed his surgical residency at UCLA before completing a fellowship in Colon and Rectal Surgery at Washington University. He returned to school in 2007 to obtain a Masters in Health Care Management from Harvard. After completing his fellowship in Colon and Rectal Surgery, Dr. Welton joined the faculty at UCSF where he became interested in anal cancer prevention through early diagnosis and treatment of anal dysplasia. He continues to be active in this field serving on an NIH scientific advisory council. Dr. Welton served on the Executive Council of the American Society of Colon and Rectal Surgeons. He is currently serving on the American Board of Colon and Rectal Surgery, the American Society of Colon and Rectal Surgeons Research Foundation, and the American Board of Surgery.
Dr. Welton continues to maintain a busy clinical practice with clinical research interests focused on quality and safety. He is active in teaching and mentoring medical students and residents, and co-founded Prescient Surgical through his involvement with the Stanford Biodesign Innovation program.
Jeremy is the design and manufacturing guru at Prescient Surgical and the creative driving force behind the company’s technology. His engineering training included deep experience in design, machining, manufacturing, and prototyping in school and during an internship at IDEO. He has prior corporate product development experience at Biomet Orthopedics, imparting design excellence, discipline, and quality into the product development process at Prescient Surgical. Jeremy earned BS and MS in Mechanical Engineering from Purdue University and University of Michigan, respectively, and afterwards attended Stanford University in the Biodesign Innovation Fellowship program.
Steve joined Prescient Surgical in October 2015 as Senior Director of Operations. He brings over 20 years of engineering, manufacturing, quality, and operational experience supporting asthma, cardiovascular, esophageal, oncology, and surgical products, both in early stage and Fortune 500 companies. Most recently, Steve worked at Viveve Medical as the Director of Operations, responsible for a wide range of activities, including Product Development & Manufacturing. Steve previously worked at Asthmatx (now Boston Scientific) as the Director of Operations, where he led the transition from R&D assembly into clinical manufacturing and managed scale-up activities for commercial release. Steve also held various leadership and technical roles at BÂRRX Medical (now Covidien), Boston Scientific, RadioTherapeutics (now Boston Scientific), Johnson & Johnson, and Guidant (now Abbott Vascular). Steve earned his M.S. degree in Engineering Management from California State University, Northridge, received his B.S. degree in Engineering from California State Polytechnic University, Pomona, and is a Certified Manufacturing Engineer.
Lisa joins Prescient Surgical with over 10 years of medical device experience from Medtronic. She has held positions in both reliability engineering and clinical research across multiple business units. Lisa also participated in a Leadership Development Rotation Program, where she spent one year in South Korea helping establish the clinical research function in that geography. Most recently, Lisa worked as a Clinical Research Manager leading the global clinical strategy and execution for their next generation renal denervation system including participation on the cross-functional development core team responsible for successfully obtaining CE Mark. Lisa holds a BS and MS degree in Biomedical Engineering from the University of Wisconsin-Madison.
Nick joined Prescient Surgical after 8 years of R&D medical device experience in similarly fast-paced start-up environments. He has contributed to all aspects of product development from design concept through manufacturing transfer at FoxHollow, Hansen Medical, and Avinger. He launched the Ocelot imaging catheter and Lightbox imaging system, and was the engineering lead for the manufacturing transfer of the Wildcat Chronic Total Occlusion (CTO) catheter. Nick also designed devices used in 6 First in Human studies outside of the U.S., where he was instrumental in providing technical support to clinical partners. He is currently listed on 7 patent applications.
Shreya joined Prescient full-time in October 2015 as Quality Engineer and Regulatory Associate following a summer internship at the Company while she completed her Master's degree. Prior to joining Prescient, she had worked in the Quality Assurance division at Tata Consultancy Services Ltd. (India) where she was responsible for testing of banking software applications. Thereafter, she obtained her Master’s degree in Biomedical Engineering from San Jose State University, with an eye towards improving the quality of medical devices. She joined Prescient to help establish and maintain the in-house Quality Management System, and her role has expanded to support regulatory, R&D, and manufacturing activities.
We were incredibly fortunate to have benefited from Ferolyn’s guidance as a founding member of Prescient. Ferolyn shepherded our nascent ideas, forged the team’s personal development, and planted the seeds that blossomed into the unique opportunity and culture that we promote today. She will be missed dearly.
Ferolyn reminded us to “Be tough—but be human!” Ferolyn balanced these qualities effortlessly and knew that strength of mind, though necessary, was not alone sufficient to improve the human condition. Sensitivity and compassion were the beacons that so brightly illuminated her powerful intellect.
At Prescient, we will honor her legacy by finishing the mission she started. We will be tough as we turn to face the challenges of building a business. And with full hearts, we will be human; ever mindful of the amazing people we’ll touch along the way.
Donald E. Fry, M.D. is Executive Vice President for Clinical Outcomes Management at MPA Healthcare Solutions, Adjunct Professor of Surgery at Northwestern University, and Professor Emeritus of Surgery at the University of New Mexico School of Medicine. At MPA Healthcare Solutions, Dr. Fry provides clinical leadership in analyzing and evaluating clinical performance, guiding quality improvement, and creating incentives for coordinated, cost-effective care. Dr. Fry is the lead developer of the Specialized Intervention modules of GlobalPRIME™.
Born in Marion, Ohio, Dr. Fry received his undergraduate and medical degrees at The Ohio State University in Columbus, Ohio. He completed a straight surgical internship at the University of Texas Southwestern Medical School in Dallas, Texas and residency in general surgery at the University of Louisville School of Medicine in Louisville, Kentucky.
In 1977, Dr. Fry joined the faculty of the Department of Surgery at the University of Louisville. Five years later, Dr. Fry was appointed Professor of Surgery at Case Western Reserve University School of Medicine in Cleveland, Ohio. In 1987, he was appointed Professor and Chairman of Surgery at the University of New Mexico, a position he held for 16 years. While at the University of New Mexico, Dr. Fry also served as Chief of Surgery and director of the trauma service at the University of New Mexico Hospital.
Dr. Fry has served on the board of governors of the American College of Surgeons and as President of the Surgical Infection Society, the Shock Society, and the Association of VA Surgeons. He is also a past president of the American College of Surgeons New Mexico Chapter, the Hiram C. Polk Surgical Society, and the Albuquerque Academy of Surgery. Dr. Fry has served on the editorial boards of nearly one dozen journals and published more than 400 scholarly papers, abstracts, book chapters, and books. His special academic interests are in the areas of surgical infection, sepsis, complications of surgical care, and more recently in the areas of clinical outcomes research and healthcare economics. In 1997, he received the Alumni Achievement Award of The Ohio State University College of Medicine.
Yuman Fong, M.D., an internationally recognized expert in hepatobiliary cancer and in the use of genetically modified viruses to combat malignant disease, is the chair of the Department of Surgery at City of Hope. Dr. Fong is also Associate Director for International Relations at the comprehensive cancer center.
Dr. Fong joined City of Hope from Memorial Sloan Kettering Cancer Center in New York, where he held the Murray F. Brennan Chair in Surgery while also serving as a professor of surgery at Cornell Medical College. He has been a pioneer both in the operating room and in the laboratory, crafting new surgical techniques and instruments and creating entirely new treatment methods. Especially notable is his track record of launching human clinical trials of genetically modified viruses with the potential to fight cancer.
Dr. Fong has authored more than 600 peer-reviewed articles, including more than 200 basic scientific articles, and over 350 clinically oriented peer-reviewed publications, which have appeared in Nature, New England Journal of Medicine and Journal of Clinical Investigation, among others. He has served as author and editor of 11 textbooks as well as 65 book chapters.
Dr. Fong has received grant support as a principal investigator continuously over the past 17 years, most from the National Institutes of Health (NIH), and has been awarded five patents related to his work. He has served on the editorial boards of 14 journals and has received numerous honors and awards including the Franklin Martin Faculty Fellowship from the American College of Surgery and the Shipley Award from the Southern Surgical Association. Dr. Fong recently completed a two-year term as chair of the recombinant DNA advisory committee of the NIH.
Thomas M. Krummel, MD has served in leadership positions in many of the important surgical societies including the American College of Surgeons, the American Pediatric Surgical Association, the American Surgical Association, the American Board of Surgery, the American Board of Pediatric Surgery, the American Board of Plastic Surgery and is currently President of the Halsted Society. He has mentored over 100 students, residents and post docs during their research training. Tom has been a pioneer and a consistent innovator in countless and diverse areas throughout his career. Most importantly, as the Co-Founder and Co-Director of the Stanford Biodesign Program, Dr. Krummel's support was instrumental in Prescient's early success, thanks to his clinical, business, and interpersonal acumen.
Motaz Qadan, MD, earned his degree at the University of Edinburgh. After starting his surgical training in the UK, he soon joined the University of Louisville for research in Surgical Site Infection under the guidance of some of the most well-recognized names in surgery. Dr. Qadan has made significant contributions to our understanding of SSI, particularly in the area of perioperative oxygen therapy. Prescient was fortunate to connect with Dr. Qadan in the rich, collaborative environment of Silicon Valley when he came to Stanford to complete his residency. He is currently in his surgical oncology fellowship at Memorial Sloan Kettering.
Michael A. Goldfarb, MD graduated from New York University School of Medicine and then completed a general surgical residency at Beth Israel Medical Center in New York City. He then served as a Major in the United States Army as Surgical Director of Wound Ballistics, 1972-1974. He helped develop Kevlar body armor and established today's standard for bullet proof body armor, and was awarded the Army Professional Commendation Medal.
He started private practice in 1974 and from 2000-2014 was Chairman and Program Director of the Department of Surgery at Monmouth Medical Center, Barnabas Health Care System. He helped train over 700 surgical residents in his career. Dr. Goldfarb is a Professor of Surgery at Drexel University School of Medicine and in 2013 he was given the Drexel University College of Medicine Award, “For setting an outstanding standard of skill and commitment in the clinical care of Patients." He has pioneered several areas of surgery including the introduction of laparoscopic cholecystectomy in April 1990 in New Jersey, and sentinel lymph node biopsy in April 1997. He also holds patents for several surgical devices, most recently having developed the “lap finger,” produced by Microline Surgical.
An active professional, he enjoys spending time with his four grandchildren, golfing, fencing, photography, magic and raising Rhodesian Ridgebacks.